Stock Markets March 31, 2026

Teladoc Shares Jump After Activist Urges $200M Buyback and Strategic Review

Pineal Capital presses Teladoc to repurchase stock, review business structure and address capital allocation as valuation sits near low multiples

By Ajmal Hussain TDOC
Teladoc Shares Jump After Activist Urges $200M Buyback and Strategic Review
TDOC

Teladoc Health stock climbed 4% following a March 31 letter from activist investor Pineal Capital Management calling for a minimum $200 million share buyback and a strategic review that could include separating the company's two principal segments. The investor accused management of sluggish decision-making and poor capital allocation, pointed to depressed valuation metrics and rising share count, and flagged potential growth drivers for the company’s mental-health business.

Key Points

  • Pineal Capital asked Teladoc to start a share buyback program of at least $200 million and to consider separating its two main business segments - impacting corporate strategy in telehealth and digital mental health.
  • The activist highlighted valuation metrics: roughly 4.18 times 2026 EV/EBITDA and 0.47 times revenue on consensus estimates, and noted the share count rose from about 90 million in 2020 to 177 million as of December 2025 - relevant to investors and equity markets.
  • Pineal flagged policy shifts and BetterHelp’s insurance-supported revenue progress (about $28 million run-rate end of 2025 with guidance toward a $100 million exit run-rate in 2026) as possible growth drivers for the healthcare and insurance sectors.

Teladoc Health Inc. (NYSE:TDOC) saw its shares rise 4% on Tuesday after activist investor Pineal Capital Management publicly urged the company to initiate a share buyback program and undertake a strategic review of its businesses.

In an open letter dated March 31, Pineal called for a share repurchase plan of at least $200 million and proposed that Teladoc consider splitting its two main operating units. The investor criticized the board for what it described as slow decision-making and poor choices in capital allocation, singling out the 2020 acquisition of Livongo as an example.

Pineal’s letter included a set of valuation and operational metrics it considered concerning. The firm noted that Teladoc currently trades at roughly 4.18 times projected 2026 enterprise value-to-EBITDA. It also highlighted that the company’s share price has fallen by more than 90% from pre-COVID highs while basic shares outstanding increased from about 90 million in 2020 to 177 million as of December 2025. According to Pineal, Teladoc has never repurchased shares since becoming a public company.

The company operates through two segments: Integrated Care, which serves employers and health plans, and BetterHelp, a mental health platform. Teladoc reports it serves more than 100 million lives, and Pineal noted the company produced over $1.1 billion in mental health-related revenue in 2025.

Pineal’s letter also pointed to recent policy shifts it sees as potential tailwinds, including permanent coverage of virtual care in high-deductible health plans and a $50 billion Rural Health Transformation Program. The investor highlighted BetterHelp’s insurance-supported revenue run-rate as reaching about $28 million by the end of 2025, and noted guidance for a $100 million exit run-rate in 2026.

To illustrate relative valuation, Pineal referenced recent transaction multiples, calling out the Talkspace acquisition at multiples of 3.0 times revenue and 25 times EBITDA. By contrast, Pineal presented Teladoc’s consensus-based multiples as approximately 0.47 times revenue and 4.18 times EBITDA. The firm warned that such depressed valuation levels could make Teladoc attractive to an opportunistic acquirer.


What happened today: Teladoc shares rose 4% following Pineal Capital’s public appeal for a buyback and strategic review.

Next steps noted by Pineal: launch a buyback of at least $200 million and evaluate separating Integrated Care and BetterHelp.

Details in this report reflect the content of Pineal Capital Management’s March 31 letter and Teladoc-related metrics cited within that letter.

Risks

  • Depressed valuation and activist pressure could make Teladoc a target for an opportunistic takeover - a risk to current corporate control and strategic direction, affecting shareholders and M&A activity in the healthcare sector.
  • Concerns raised about past capital allocation, including the 2020 Livongo acquisition, point to ongoing uncertainty about management decisions and board effectiveness - a governance risk for investors in telehealth and digital health platforms.
  • If the company does not act on activist demands for a buyback or strategic changes, investor dissatisfaction could persist and maintain pressure on the stock - a market risk impacting equity performance in the healthcare and technology-focused segments.

More from Stock Markets

U.S. Customs Outlines Phased Refund System for IEEPA Tariffs, Warns Reviews Could Take 45 Days Mar 31, 2026 Vitol’s U.S. Gasoline Chief John Addison to Retire at 47, Sources Say Mar 31, 2026 Ermotti to Lead UBS Through 2027, Signals Potential for Longer Tenure Mar 31, 2026 Stocks Swing Across Market Caps as Nvidia, Marvell, and Several Tech Names Lead Gains Mar 31, 2026 RBC Flags Risks in Unilever-McCormick Food Transaction Mar 31, 2026